2024-07-13发表于上海
2024-04-04发表于上海
2024-02-04发表于陕西省
2023-11-18发表于加利福尼亚
2023-04-16发表于香港
2023-03-07发表于上海
2022-05-08
2020-12-02
2020-12-02
2020-10-31
2020-10-29
没有完全理解这个机制。一般来说，#雌激素#应该是不利的，应该用雌激素拮抗剂才对，为什么用受体激动剂#TTC-352#来治疗#乳腺癌#呢？看了一下原文，这样描述：TTC-352 is a selective human estrogen receptor partial agonist (ShERPA). TTC-352 is designed to treat metastatic ER+ breast cancers that have progressed on first-line endocrine therapy and a CDK4/6 inhibitor. TTC-352 is expected to be effective in breast cancer patients that develop resistance to endocrine therapy (est. 625,000 patients). 确实是雌激素受体部分激动剂(ShERPA)，以后再多研究研究
2020-08-29
2020-08-22
